Search results for "AOC"

showing 10 items of 504 documents

Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.

2010

. Purpose:  The purpose of this study was to investigate the tolerability and intraocular pressure (IOP) reducing effect of the first preservative-free prostaglandin tafluprost (Taflotan®) in patients exhibiting ocular surface side-effects during latanoprost (Xalatan®) treatment. Methods:  A total of 158 patients were enrolled in this open-label multicentre study. Eligible patients had to have at least two ocular symptoms, or one sign and one symptom, during treatment with latanoprost. At baseline, the patients were directly switched from latanoprost to preservative-free tafluprost for 12 weeks. The patients were queried for ocular symptoms, and ocular signs were assessed by using tear brea…

MaleIntraocular pressuregenetic structuresmedicine.medical_treatmentAdministration TopicalMucin 5ACmedicine.disease_causeExfoliation SyndromeConjunctival Diseaseschemistry.chemical_compoundSurveys and QuestionnairesMedicineLatanoprostAged 80 and overBlepharitisGeneral MedicineMiddle AgedTolerabilityPatient SatisfactionAnesthesiaProstaglandins F SyntheticLatanoprostFemalemedicine.symptomIrritationBenzalkonium CompoundsGlaucoma Open-Anglemedicine.drugAdultGonioscopyHyperemiaTonometry OcularHumansBlepharitisAntihypertensive AgentsIntraocular PressureAgedGlaucoma medicationbusiness.industryPreservatives PharmaceuticalProstaglandins FTafluprostHLA-DR Antigensmedicine.diseaseeye diseasesOphthalmoscopyOphthalmologychemistryQuality of LifeItchingOcular Hypertensionsense organsbusinessActa ophthalmologica
researchProduct

European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma

2020

indexation en cours.; PURPOSE: This study investigated the efficacy and safety of a cross-linked collagen stent (XEN 45) with or without cataract surgery in the treatment of glaucoma. SETTING: Real-life setting. DESIGN: Prospective, open-label, multicenter clinical trial. METHODS: Eligible patients with glaucoma inadequately controlled by treatment, or poor compliance or intolerance to topical therapy were included. Patients were divided into those with implant only (solo group; phakic and pseudophakic patients) and implant combined with cataract surgery (combo group). Differences in average intraocular pressure (IOP) and number of medications between baseline and study end (12 months), and…

MaleIntraocular pressuregenetic structuresmedicine.medical_treatmentVisual AcuityGlaucomasurgery0302 clinical medicineLens Implantation IntraocularimplantationProspective StudiesGlaucoma Drainage ImplantsAged 80 and overDry needlingMiddle AgedSensory Systems3. Good healthEuropeTreatment OutcomeFemaleStentsGlaucoma Open-Anglesafetymedicine.medical_specialtyintraocular-pressurepredictive-value03 medical and health sciencesTonometry OcularmedicineHumans[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrganssuccessIntraocular PressureAgedbusiness.industryStentPhacoemulsificationCataract surgerymedicine.diseaseeye diseasesSurgeryClinical trialOphthalmologyphacoemulsification030221 ophthalmology & optometryImplantsense organsbusiness030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Effect of bicycle ergometer test on intraocular pressure in elderly athletes and controls.

2009

To evaluate the effect of intensive physical exercise on intraocular pressure (IOP) in 66- to 85-year-old subjects IOP was measured before and after a maximal bicycle ergometer test. The non-glaucomatous subjects comprised 85 males and 36 female athletes and 16 male and 22 female controls of corresponding age drawn from a population register. IOP was measured using a non-contact tonometer. The results indicated a decrease (> or = 2 mmHg) in 34% of the subjects, no change in 57% and an increase in 9%. The decrease was more pronounced in subjects with higher pre-test values. In all four subjects with a pre-test value above 22 mmHg a reduction from 4 to 11 mmHg was observed. The change in IOP …

MaleIntraocular pressuremedicine.medical_specialtyAginggenetic structuresPhysical ExertionGlaucomaPhysical exerciseElectrocardiographyRandom AllocationMedicineHumansIntraocular PressureAgedAged 80 and overbiologybusiness.industryAthletesGeneral Medicinemedicine.diseasebiology.organism_classificationeye diseasesTest (assessment)Intensity (physics)OphthalmologyAnesthesiaPhysical therapyExercise TestFemalesense organsBicycle ergometerbusinessPopulation RegisterGlaucoma Open-AngleSportsActa ophthalmologica
researchProduct

Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension

2014

Introduction Fixed-combination intraocular pressure (IOP)—lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP. The aim of this study was to evaluate the safety and efficacy of fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC) versus concomitant administration of brinzolamide 1% plus brimonidine 0.2% (BRINZ + BRIM) in patients with open-angle glaucoma or ocular hypertension. Methods This was a prospective, phase 3, multicenter, double-masked, 6-month trial. Patients who had insufficient IOP control with monotherapy or who were receiving 2 IOP-lowering medications were randomized 1:1 to receive twice-dail…

MaleIntraocular pressuremedicine.medical_specialtyConcomitantgenetic structuresIntraocular pressureBrinzolamideThiazinesOcular hypertensionGlaucomaOcular hypertensionlaw.inventionTonometry OcularRandomized controlled trialDouble-Blind MethodlawOphthalmologyQuinoxalinesConcomitant TherapyMedicineHumansPharmacology (medical)Fixed combinationCarbonic anhydrase inhibitorAntihypertensive AgentsOriginal ResearchAgedMedicine(all)Sulfonamidesbusiness.industryBrimonidineAlpha-2 agonistSimbrinza®GlaucomaGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesDysgeusiaOphthalmologyDrug CombinationsTreatment OutcomeBrimonidine TartrateFemalesense organsmedicine.symptombusinessGlaucoma Open-Anglemedicine.drugAdvances in Therapy
researchProduct

Posterior‐chamber phakic implantable collamer lenses with a central port: a review

2020

Abstract We aimed to summarize the outcomes reported following the implantation of the V4c implantable collamer lens with a central port (ICL, STAAR Surgical Inc) for myopia correction. A literature search in PubMed, Web of Science and Scopus was carried out to identify publications reporting clinical outcomes of patients who were implanted with the V4c ICL model and had a follow‐up period of at least 6 months. A total of 35 clinical studies published between 2012 and 2020 were included in the present review. A comprehensive analysis of the available data was performed, focusing on visual and refractive outcomes at different time‐points post‐surgery. In addition, adverse events and other pa…

MaleIntraocular pressuremedicine.medical_specialtyPhakic Intraocular LensesVisual acuityWeb of sciencevisual acuityReview ArticleRefraction Ocular03 medical and health sciences0302 clinical medicinePort (medical)vaultLens Implantation IntraocularOphthalmologymedicineMyopiaphakicHumansReview ArticlesIntraocular PressureImplantable collamer lensrefractionbusiness.industryimplantable collamer lensGeneral Medicineadverse eventsEndothelial cell densityOphthalmology030221 ophthalmology & optometryFemalemedicine.symptombusiness030217 neurology & neurosurgeryActa Ophthalmologica
researchProduct

Deep sclerectomy versus trabeculectomy with low-dosage mitomycin C: four-year follow-up

2006

<i>Aims:</i> To compare the long-term effects of low-dosage mitomycin C (MMC) in both deep sclerectomy (DSMMC) and trabeculectomy (TPMMC) on intraocular pressure (IOP). <i>Methods:</i> Analysis of extended follow-up of data from a prospective clinical trial. Forty patients were originally randomised to undergo either DSMMC (19 eyes) or TPMMC (21 eyes). Follow-up was performed at postoperative day 1, weeks 1, 2 and 3, as well as months 1, 3, 6, 9, 12, 18, 24, 36 and 48. Two- to three-week data were not included in the statistical analysis. Postoperative complications, number of antiglaucoma medications and IOP were recorded at each visit. Complete (no medications) and…

MaleIntraocular pressuremedicine.medical_specialtygenetic structuresMitomycinmedicine.medical_treatmentEye diseaseGlaucomaKaplan-Meier EstimateExfoliation Syndromelaw.inventionPostoperative ComplicationsRandomized controlled triallawOphthalmologyGlaucoma surgerymedicineHumansTrabeculectomyIntraocular PressureAgedmitomycin CIntraoperative CareDose-Response Relationship Drugbusiness.industrySettore MED/30 - Malattie Apparato VisivoMitomycin Ctrabeculectomydeep sclerectomyclinical trialGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesSensory SystemsSurgeryClinical trialOphthalmologyTreatment OutcomeSclerostomyFemalesense organsbusinessGlaucoma Open-AngleFollow-Up Studies
researchProduct

E-PTFE (Gore-Tex) implant with or without low-dosage mitomycin-C as an adjuvant in penetrating glaucoma surgery: 2 year randomized clinical trial.

2008

Purpose: To test the expanded polytetrafluoroethylene (ePTFE) as a new adjuvant in trabeculectomy. Methods: Consecutive glaucoma surgical inpatients were observed at the Department of Ophthalmology of Palermo University. Sixty patients (60 eyes) were randomly assigned to undergo trabeculectomy (T), trabeculectomy with mitomycin-C (TMMC), with ePTFE (TG) or with mitomycin-C and ePTFE (TGMMC). Postoperative visits were scheduled at 24 hr, 7 days, 1, 3, 6, 12, 18 and 24 months. Complete success and qualified success were assessed at two target intraocular pressure (IOP) levels – £21 and £17 mmHg – by Kaplan–Meier curves. Results: The postoperative IOP reduction was significant (P < 0.01) at th…

MaleIntraocular pressuremedicine.medical_specialtygenetic structuresmedicine.medical_treatmentMitomycinGlaucomaOcular HypotensionTrabeculectomyKaplan-Meier Estimatelaw.inventionRandomized controlled triallawpenetrating glaucoma surgerymedicineGlaucoma surgeryTrabeculectomyHumansPostoperative PeriodSurvival ratePolytetrafluoroethyleneIntraocular PressureE-PTFE (Gore-Tex)implantAgedDose-Response Relationship Drugbusiness.industryMitomycin CGlaucomaGeneral MedicineProstheses and ImplantsMiddle Agedmedicine.diseaserandomized clinical trialSurgerylow-dosage mitomycin-Cpenetrating glaucoma surgery; E-PTFE (Gore-Tex)implant; low-dosage mitomycin-C; randomized clinical trialOphthalmologyChemotherapy AdjuvantAnesthesiaFemaleImplantbusiness
researchProduct

Biodegradable collagen matrix implant vs mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial

2011

AIM: To verify the safety and efficacy of Ologen (OLO) implant as adjuvant compared with low-dosage mitomycin-C (MMC) in trabeculectomy. METHODS: This was a prospective randomized clinical trial with a 24-month follow-up. Forty glaucoma patients (40 eyes) were assigned to trabeculectomy with MMC or OLO. Primary outcome includes target IOP at ≤21, ≤17, and ≤15 mm Hg; complete (target IOP without medications), and qualified success (target IOP regardless of medications). Secondary outcomes include bleb evaluation, according to Moorfields Bleb Grading System (MBGS); spectral domain optical coherence tomography (SD-OCT) examination; number of glaucoma medications; and frequency of postoperative…

MaleIntraocular pressuremedicine.medical_specialtymedicine.medical_treatmentMitomycinGlaucomaTrabeculectomyMatrix (biology)law.inventionRandomized controlled triallawAbsorbable ImplantsmedicineTrabeculectomyHumansProspective StudiesIntraocular PressureAgedGlycosaminoglycansIntraoperative CareSettore MED/30 - Malattie Apparato Visivobusiness.industryMitomycin CGlaucomaProstheses and ImplantsMiddle AgedOlogen MMC trabeculectomymedicine.diseaseSurgeryOphthalmologyCross-Linking ReagentsClinical StudyFemaleImplantCollagenbusinessAdjuvantTomography Optical Coherence
researchProduct

Dietary polyunsaturated fatty acids reduce retinal stress induced by an elevation of intraocular pressure in rats.

2011

International audience; N-6 and n-3 polyunsaturated fatty acids (PUFAs) have been shown to prevent tissue release of inflammatory molecules. We have shown that a combination of n-6 and n-3 PUFAs is more efficient than single supplementations on the long-term consequences of intraocular pressure elevation. We hypothesized that such an association is also more effective during early retinal stress by modifying retinal proinflammatory prostaglandin and cytokine productions. Rats were supplemented for 3 months with n-6 PUFAs, n-3 PUFAs, or both n-6 and n-3 PUFAs. After 3 months, a surgical elevation of intraocular pressure was induced. Retinal morphometry and glial cell activation were evaluate…

MaleMESH : RNA MessengerMESH: Eicosapentaenoic AcidEndocrinology Diabetes and Metabolismmedicine.medical_treatment[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionInterleukin-1betaMESH: Dietary SupplementsMESH: Rats Sprague-DawleyRats Sprague-Dawleychemistry.chemical_compound0302 clinical medicineEndocrinologyMESH: Interleukin-1betaratMESH: AnimalsProstaglandin E2Prostaglandin E1MESH : Tumor Necrosis Factor-alphaMESH : Intraocular Pressure0303 health sciencesNutrition and DieteticsMESH : RatsMESH : NeurogliaMESH: RetinaMESH: Dinoprostonepression intraoculaireMESH: AlprostadilMESH: Docosahexaenoic AcidsBiochemistryEicosapentaenoic AcidDocosahexaenoic acidlipids (amino acids peptides and proteins)MESH: NeurogliaProstaglandin D2Cell activationNeurogliaMESH : Alprostadilmedicine.drugProstaglandin Emedicine.medical_specialtyMESH : DinoprostoneMESH : Interleukin-6Docosahexaenoic AcidsMESH: RatsMESH : MaleProstaglandinBiologyMESH : Interleukin-1betaDinoprostoneRetinaMESH : Diet03 medical and health sciencesMESH: DietMESH: Intraocular PressureInternal medicinemedicineMESH : Eicosapentaenoic AcidAnimalsMESH : Dietary SupplementsRNA MessengerAlprostadilprostanoids030304 developmental biologyMESH: RNA MessengerInterleukin-6Tumor Necrosis Factor-alphadietary polyunsatured fatty acidretinal stressMESH : RetinaRetinalN-6MESH: Interleukin-6MESH : Rats Sprague-Dawleyeye diseasesMESH: MaleMESH : Docosahexaenoic AcidsDietRatsN-3EndocrinologychemistryMESH: Tumor Necrosis Factor-alphaDietary Supplements030221 ophthalmology & optometryMESH : Animalssense organs[SDV.AEN]Life Sciences [q-bio]/Food and Nutritionintraocular pressure
researchProduct

Does general anesthesia have a clinical impact on intraocular pressure in children?

2016

Summary Background Reliable measurement of intraocular pressure (IOP) is crucial in pediatric patients with suspected glaucoma. General anesthesia (GA) is usually needed in infants to allow a thorough examination. However, anesthesia itself may influence IOP, depending on the type used and the depth of sedation. The purpose of this study was to evaluate the normal distribution of IOP during GA in healthy children and to analyze differences in IOP relative to the anesthetics used and the measurement time point. Methods Approval for this observational study was received from the local institutional review boards and written informed consent was obtained from the children's parents. A total of…

MaleMethyl EthersIntraocular pressuregenetic structuresSedationmedicine.medical_treatmentRemifentanilAnesthesia GeneralSevofluraneRemifentanil03 medical and health sciencesSevoflurane0302 clinical medicinePiperidines030202 anesthesiologyHeart rateMedicineHumansProspective StudiesChildPropofolIntraocular PressureMechanical ventilationbusiness.industryInfanteye diseasesAnesthesiology and Pain MedicineBlood pressureAnesthesiaChild PreschoolPediatrics Perinatology and Child HealthAnesthetics Inhalation030221 ophthalmology & optometryFemalesense organsmedicine.symptombusinessPropofolAnesthetics Intravenousmedicine.drugPaediatric anaesthesia
researchProduct